V1RI2 Inhibitors
V1RI2 inhibitors encompass a diverse range of chemical compounds that indirectly impact the functional activity of the V1RI2 receptor through various signaling pathways and cellular processes. Amiloride, for instance, though primarily known as a potassium-sparing diuretic that inhibits sodium channels, may disrupt ion gradients critical for V1RI2 signaling, thus indirectly affecting its activity. Similarly, propranolol, as a non-selective beta-adrenergic receptor antagonist, modifies sympathetic nervous system activity, which could lead to downstream effects on V1RI2 expression or function. Losartan's antagonism of the angiotensin II receptor and yohimbine's blockade of alpha-2 adrenergic receptors both alter significant hormonal and neurotransmitter systems that could influence the operational context of V1RI2.
Moreover, ondansetron and haloperidol, antagonists of serotonin 5-HT3 and dopamine D2 receptors, respectively, may modulate neural circuits in a manner that indirectly affects V1RI2 signaling. The influence of calcium channel blockers such as verapamil, diltiazem, and nifedipine on V1RI2 is predicated on their ability to reduce calcium influx, which is often integral to cellular signaling and excitability. This might lead to a modulation of V1RI2 activity, particularly in calcium-dependent pathways. Tetrodotoxin's role in this array of inhibitors is unique due to its potent blockade of voltage-gated sodium channels; by preventing action potential propagation, it could indirectly impede neurotransmission that influences V1RI2 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Amiloride is a potassium-sparing diuretic that inhibits sodium channels. V1RI2, being a receptor, may utilize ion channels for signaling. Blocking sodium channels can disrupt ion gradients, potentially affecting V1RI2 signaling. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist. It can indirectly inhibit V1RI2 by modulating the sympathetic nervous system activity that might regulate V1RI2 expression or function. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist that may indirectly affect V1RI2 by altering the renin-angiotensin system, which could impact V1RI2's functional context. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Ondansetron is a serotonin 5-HT3 receptor antagonist. By altering serotonin signaling, it could modulate neural circuits that indirectly influence V1RI2 activity. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine is an alpha-2 adrenergic receptor antagonist that can increase noradrenaline release. This altered adrenergic signaling could indirectly affect V1RI2's functional role. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is an L-type calcium channel blocker. By inhibiting calcium influx, it could reduce cellular excitability and signaling, potentially impacting V1RI2 function. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Atropine is a muscarinic acetylcholine receptor antagonist. It can modify parasympathetic activity, which might indirectly influence V1RI2's signaling pathways. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem is a calcium channel blocker that can decrease calcium-dependent signaling, potentially modulating pathways that regulate V1RI2's activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is another calcium channel blocker that may reduce calcium-mediated signaling events, potentially altering the functional activity of V1RI2. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is a dopamine D2 receptor antagonist. Dopaminergic signaling modulation could impact neural networks and indirectly affect V1RI2 signaling. | ||||||